# MATTERHORN (NCT04592913)

> Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04592913
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Gastrointestinal Neoplasms; Esophagogastric Junction
- Interventions: Durvalumab; FLOT chemotherapy
- Enrollment: 957
- Primary outcome: Event-free survival (EFS)

## Indexed commentary on MATTERHORN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 334
- YouTube: 175
- Podcasts: 121
- Bluesky threads: 25
- X videos: 13

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=matterhorn-nct04592913

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04592913", "email": "<work email>"}; the inbox owner confirms by the emailed link.